Our History

Pascal Doguet holds a PhD in electronics from the UCLouvain. During his thesis, he was involved in the development of a visual prosthesis, designing the prosthesis electronics and application specific integrated circuits. He worked at Neurotech as Chief Technology Officer, in charge of the R&D department and responsible for the development of the vagus nerve stimulator and other industrial projects involving implants for Deep Brain Stimulation and Sleep Apnea that he entirely designed. Multilingual and driven by challenges, he also has extensive experience in coordinating research projects at national and international levels.

Guillaume followed the cursus of Commercial Engineering at the Namur University. He then combined 6 years of consulting with Deloitte Strategy and Operation and more than 10 years as CFO for different start-ups in Biotech (Univercells, Masthercell, OncoDNA, etc). He has a strong experience in strategic consulting for SME and start-up, including the development of marketing and financial business plans.
He is partner and manager at beLean, a company which provides services in strategy, finance and management. He started working with Synergia Medical in this context. He became CFO of Synergia Medical in 2019.

Sophie Baratte was the General Manager of Johnson & Johnson France and the Sorin Group, before becoming the CEO of CitoxLab in 2009. She then continued her career as EMEA S&M VP for Lifecell and as CEO of Cellnovo Group. She has a good experience in the US Market and a good understanding of all health and economics environments across Europe.

She studied Life Sciences Engineering in France. She holds a PhD in Biotechnologies and an MBA from the HEC Paris.

Yves Jongen, a Belgian national, born on October 27^th, 1947, is a Civil Engineer in electronics with an additional certification in nuclear sciences. After having managed the Catholic University of Louvain-la-Neuve’s Cyclotron Research Center, he founded Ion Beam Applications (IBA) in 1986. Currently Chief Research Officer, he is a member of the executive committee. He is the author of over a dozen patents and more than 200 publications in the particle accelerator field.

Furthermore, Yves Jongen is the Chairman of the Board of the Industry cluster “Pôle MecaTech” as well as a member of the Royal Academy of Sciences in the class Technology and Society.

Marc Nolet de Brauwere was appointed CEO of PhysIOL in 1997 when he took over the company. He previously held different positions at Petrofina S.A. in the US and as an associate at McKinsey.

He is currently an Independent Director at Cardiatis, Mymicroinvest, Endo Tools Therapeutics, Biotech Coaching, iSTAR Medical and Aliaxis and is currently a Member of the Ashoka Support Network.

He holds a Master’s degree in Civil Mining Engineering from the Université Catholique de Louvain, Belgium and a Master’s degree in Industrial Management from the Katholieke Universiteit Leuven.

Pierre DETRIXHE is Investment Manager at INVESTSUD Group. Prior to that, he worked as Technology Transfer Officer and Scientist in biotechnology. He holds a master in Bioengineering (ULiège) and a master in Management (UCL). 
At INVESTSUD Group, Pierre manages the “Financière spin-off luxembourgeoise” which is a specialized vehicle investing in seed and early-stage technological start-ups. The portfolio companies features some of the regional leading tech companies mainly in the Life Sciences and in the Medtech Industries.

Els Hubloux is a Partner at Newton Biocapital Partners. She has over 23 years of experience in the life sciences sector, of which 17 years as a venture capital professional. She has also acted as CFO of a diagnostics start-up and has been a director of a number of life sciences and medtech companies. She holds a Master’s degree in chemical engineering.

Dr. Yves Joseph Ribeill, Ph.D. Founded Scynexis, Inc (NASDAQ: SCYX) and served as its President from November 1999 to July 2015 and served as its Chief Executive Officer from November 1999 to April 1, 2015. Prior to organizing Scynexis, Inc. in 2000, Dr. Ribeill served various positions during the 25 years of his international career with Rhone-Poulenc, Aventis including Discovery Chemistry Group leader for Anti-Viral Research and later in the Central Nervous System Group in France. He served as Group Leader in the Cardiovascular Group in England. Upon his return to France, Dr. Ribeill served as Director of Chemistry for the Anti-Infective Group. He was involved in all phases of the drug discovery and development effort that resulted in the FDA approval of multiple drugs. He has been a Director of various Biotech companies in Europe including Ogeda in Belgium and in the US. He served as a Director of Scynexis, Inc. from November 1999 to March 16, 2016. He is the author of more than 26 publications and 15 patents. He was a member of the Scientific Advisory Committee of the World Health Organization and of the Medicine Malaria Venture in Geneva. Dr. Ribeill has a Ph.D. in Chemistry from the University of Montpellier (France).

Pascal Doguet holds a PhD in electronics from the UCLouvain. During his thesis, he was involved in the development of a visual prosthesis, designing the prosthesis electronics and application specific integrated circuits. He worked at Neurotech as Chief Technology Officer, in charge of the R&D department and responsible for the development of the vagus nerve stimulator and other industrial projects involving implants for Deep Brain Stimulation and Sleep Apnea that he entirely designed. Multilingual and driven by challenges, he also has extensive experience in coordinating research projects at national and international levels.

Attila Borbath’s M.Sc. in Business Administration and Engineering from the UCLouvain followed by the CEMS Master’s in International Management naturally brought him to pave his professional way in a technological start-up in the finance sector for 10 years.

In parallel, he obtained his Airline Transport Pilot License. He was then convinced by the idea of joining an innovative technology start-up where he had the role of VP Sales & Marketing. In 2013 he moved to Synergia Medical that he co-founded. Well-travelled, multilingual and energetic, Attila has developed remarkable management, entrepreneurial, marketing and business development skills.